Metabolism: clinical and experimental
Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.
Emir Muzurović, Niki Katsiki, Špela Volčanšek, Fulvio Plescia, Manfredi Rizzo, Christos S Mantzoros
Published: 202610.1016/j.metabol.2026.156494
Abstract
While the use of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) has achieved a central position in our therapeutic armamentarium, new and innovative incretin- and multi-agonist-based treatment strategies hold further promise as potential gam…
Preview only. Read the full abstract at the source